Kim Pettersson
Lund University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kim Pettersson.
The Journal of Urology | 2000
Charlotte Becker; Timo Piironen; Kim Pettersson; Thomas Björk; Kirk J. Wojno; Joseph E. Oesterling; Hans Lilja
PURPOSEnTo investigate the clinical value of measuring human glandular kallikrein 2 (hK2) compared with free and total prostate specific antigen (PSA-F and PSA-T) in serum from patients with prostate disease.nnnMATERIALS AND METHODSnSerum from healthy controls, from men with benign prostate hyperplasia (BPH), clinically localized prostate cancer (PCa), and advanced PCa were analyzed for hK2 (using an in-house-research assay with detection limit of 0.05 ng./mL and <0.1% cross-reaction with PSA) and for PSA-F and PSA-T (using the Dual Prostatus assay from EG&G Wallac).nnnRESULTSnHK2 concentrations were <0.05 ng./mL in 50/50 healthy volunteers but significantly higher (p <0.0001) and > or =0.05 ng./mL in 28/54 (52%) patients with BPH. In comparison to these men, the hK2 levels were significantly higher (p <0.0001, median 0.085 ng./mL) and > or =0.05 ng./mL in 100/136 (74%) men with clinically localized PCa. Compared with localized PCa, the hK2 levels were significantly higher (p <0.0001, median 0.57 ng./mL) and > or =0.05 ng./mL in 55/57 (96%) patients with advanced PCa. The median hK2 levels ranged from 1.3 to 1.6% of those of PSA-T in all three patient groups, whereas percent hK2/PSA-F and hK2 x PSA-T/PSA-F levels were significantly higher in cancer patients compared with those with BPH. In the discrimination of clinically localized PCa from BPH, hK2 x PSA-T/PSA-F gave the largest area under the receiver operating curve (AUC = 0.81) and significantly (p = 0.025) larger AUC than PSA-T alone (0.70). Further, at 95% sensitivity there was significant gain in specificity, and at specificity levels of 90 to 95% there was significant gain in sensitivity using the measurements of PSA-T+PSA-F+hK2 compared with analysis of PSA-T and/or percent free PSA.nnnCONCLUSIONSnDiscrimination of patients with benign prostate disease from those with prostate cancer was significantly enhanced using measurements of hK2 in addition to those of PSA-T and PSA-F. Percent hK2/PSA-F was higher in PCa than in BPH, a phenomena not yet understood.
Clinical Chemistry | 1996
Timo Piironen; Janita Lövgren; Matti Karp; Riitta Eerola; Åke Lundwall; Barry L. Dowell; Timo Lovgren; Hans Lilja; Kim Pettersson
Biochemical and Biophysical Research Communications | 1995
Janita Lövgren; Timo Piironen; C. Overmo; Barry L. Dowell; Matti Karp; Kim Pettersson; Hans Lilja; Åke Lundwall
Archive | 1994
Antti Iitiä; Timo Nils-Erik Lövgren; Kim Pettersson
Archive | 1997
Kim Pettersson; Timo Nils-Erik Lövgren
Archive | 2001
Kim Pettersson; Hans Lilja; Timo Lövgren; Pauliina Niemelä
Archive | 2000
Sanna-Maria Käkönen; Heikki Luukinen; Kim Pettersson; Timo Lövgren; H. Kalervo Väänänen
Archive | 2004
Jukka Hellman; Sanna-Maria Käkönen; Matti Karp; Timo Lövgren; H. Vaananen; Kim Pettersson
Archive | 1994
Timio Nils-Erik Lövgren; Antti Iitiä; Kim Pettersson
Archive | 2015
Vincent Linder; David Steinmiller; Kim Pettersson; Timo Lövgren; Hans Lilja; Andrew J. Vickers; Peter T. Scardino